JPRN-UMIN000017702已完成未知
KADCYLA drug use surveillance - KADCYLA drug use surveillance
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 250
研究概览
简要总结
The adverse drug reaction incidence rate in 250 examples of safety analysis was 69.60% (174/ 250 example), and the case number was 438, and platelet decreased number 54.40% (136/250 examples), aspartic acid AMINOTORANSUFERAZE increased 31.20 % (78/250 examples), ARANINAMINOTORANSUFERAZE increased 20.00 % (50/250 examples), liver function abnormal 8.00 % (20/250 examples) and nose bleeding 6.80 % (17/250 examples) met main adverse drug reactions (5% or more than of adverse drug reaction incidence rate).
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •No criteria
研究者
相似试验
已完成
不适用
Stamaril ResearchYellow feverJPRN-jRCTs031180027Ohmagari Norio11,287
已完成
Unknown
TRIBIK Drug Use SurveillanceJPRN-jRCT1080223795The Research Foundation for Microbial Diseases of Osaka University921
已完成
4 期
A postmarketing all-case surveillance of mogamulizumab in patients with CCR4 positive relapsed or refractory adult T cell lymphoma-leukemiaCCR4-positive relapsed or refractory adult T cell leukemia-lymphomaJPRN-UMIN000025368Kyowa Kirin Co., Ltd.597
已完成
不适用
Prospective observational study on efficacy and safety of PEGASYS for the treatment of patients with HBeAg positive or HBeAg negative chronic active hepatitis BJPRN-UMIN000008045Chugai Pharmaceutical Co., Ltd.536
已完成
不适用
General Drug Use Surveillance (All-Patient Surveillance) of POLIVY for Intravenous Infusion 30mg and 140mg (polatuzumab vadotin [genetical recombination]) -Relapsed or refractory diffuse large B-cell lymphomaRelapsed or refractory diffuse large B-cell lymphomaJPRN-UMIN000043840Chugai Pharmaceutical Co. Ltd.1,877